Legal Guide · Updated March 2026

Is Compounded Semaglutide Still Legal in 2026?

The legal status of compounded semaglutide has shifted multiple times since 2022. I have tracked this closely across 54+ telehealth providers, and the situation in 2026 is more nuanced than most headlines suggest. Here is where things actually stand, what it means for patients, and what your options are if you are currently on compounded semaglutide.

The short version: the answer depends on whether semaglutide is still on the FDA’s drug shortage list, what type of compounding pharmacy you are using, and what state you live in. This is not a simple yes or no question, and anyone giving you a one-line answer is oversimplifying it.

A Quick History: How Compounded Semaglutide Became So Common

To understand where we are in 2026, you need to know how we got here.

In 2022, the FDA placed semaglutide on its official drug shortage list. Demand for Ozempic and Wegovy had exploded as word spread about their weight loss effects. Novo Nordisk, the sole manufacturer of both drugs, could not keep up with production. Patients with prescriptions were showing up at pharmacies and finding empty shelves.

Under federal law (specifically the Federal Food, Drug, and Cosmetic Act, Section 503A and 503B), compounding pharmacies are allowed to create copies of FDA-approved drugs during a shortage. This is a safety valve designed to keep patients from going without critical medications. When semaglutide hit the shortage list, compounding pharmacies stepped in to fill the gap.

The result was an explosion of compounded semaglutide products. Dozens of telehealth startups launched around compounded versions, offering monthly prices between $149 and $299 compared to brand-name costs of $892 to $1,349 per month. Our guide to the cheapest GLP-1 options tracks current pricing across providers.

By mid-2023, compounded semaglutide had become a massive market. Some estimates put it at over $1 billion in annual revenue across compounding pharmacies and the telehealth platforms they partnered with. That got Novo Nordisk’s attention.

The FDA Shortage List: What Changed

The critical legal question revolves around one thing: whether semaglutide remains on the FDA’s official drug shortage list.

When a drug is on the shortage list, compounding pharmacies have a legal basis to produce it under 503A and 503B regulations. When a drug comes off the shortage list, the legal basis narrows significantly, though it does not disappear entirely (more on this below).

Here is the timeline:

• 2022: Semaglutide added to the FDA drug shortage list due to supply constraints at Novo Nordisk.
• 2023: Shortage persists. Compounding pharmacies ramp up production. Telehealth providers build business models around compounded semaglutide.
• Late 2023 to 2024: Novo Nordisk increases manufacturing capacity. The FDA begins signaling that the shortage may be resolved.
• 2024: The FDA evaluates whether to remove semaglutide from the shortage list. Multiple rounds of public comment and industry lobbying follow.
• 2025: FDA removes certain dosage forms of semaglutide from the shortage list while others remain in flux. The situation varies by specific product and dosage.

The key point for 2026: the legal ground for compounding semaglutide has narrowed compared to 2022 and 2023. If the shortage is resolved for a specific dosage form, compounding pharmacies lose their primary legal justification for producing that form. But the details matter, and the transition has not been clean or immediate.

503A vs. 503B Pharmacies: A Critical Distinction

Not all compounding pharmacies operate under the same rules, and this distinction matters enormously for the legal question.

503A pharmacies compound medications based on individual patient prescriptions. A doctor writes a prescription for a specific patient, and the pharmacy makes that specific preparation. These are typically smaller, state-regulated pharmacies. Under 503A rules, a pharmacy can compound a copy of an FDA-approved drug if certain conditions are met, including that the drug is not “essentially a copy” of a commercially available product unless that product is on the shortage list.

503B pharmacies (also called outsourcing facilities) operate at a larger scale. They can produce medications in bulk without patient-specific prescriptions, essentially functioning as small-scale manufacturers. They are registered with the FDA and subject to current Good Manufacturing Practices (cGMP). The rules for 503B facilities are different, and the shortage list exemption works differently for them.

Here is why this matters in 2026:

When semaglutide was on the shortage list, both types of pharmacies had clear legal authority to compound it. As the shortage resolves, 503A pharmacies face the most immediate legal pressure, because their exemption to copy commercially available drugs is directly tied to the shortage status.

Some 503B facilities have argued they can continue compounding semaglutide if they are using it as a “component” in a formulation that is not “essentially a copy” of the brand-name product. For example, combining semaglutide with B12 or other ingredients to create a different formulation. This argument is legally contested, and the FDA has not fully settled it as of early 2026.

Novo Nordisk’s Legal Campaign Against Compounders

Novo Nordisk has not been passive about protecting its market. The company has launched an aggressive legal campaign against compounding pharmacies producing semaglutide.

Key actions include:

Cease-and-desist letters. Starting in late 2023, Novo Nordisk sent letters to dozens of compounding pharmacies demanding they stop producing semaglutide products. Many smaller pharmacies complied rather than face litigation.

Federal lawsuits. Novo Nordisk filed suits against several compounding pharmacies and telehealth platforms, alleging trademark infringement (for using the names “semaglutide,” “Ozempic,” or “Wegovy” in marketing), patent violations, and violations of the FDCA’s compounding regulations. Several of these cases have resulted in settlements or injunctions that shut down specific compounders.

FDA lobbying. Novo Nordisk has pushed the FDA to remove semaglutide from the shortage list and to enforce more strictly against compounders. The company has argued that the shortage is resolved and that compounded semaglutide poses safety risks due to lack of FDA approval for those specific preparations.

State board complaints. In some cases, Novo Nordisk has filed complaints with state pharmacy boards against compounding pharmacies, triggering investigations and, in some instances, license suspensions.

The practical impact: the number of pharmacies actively compounding semaglutide has decreased from its peak in 2023 and 2024. The ones that remain tend to be larger, better-funded operations with legal teams capable of defending their practices.

What About Compounded Tirzepatide?

Tirzepatide (the active ingredient in Mounjaro and Zepbound) has followed a different path than semaglutide, and the two should not be confused.

Tirzepatide was also placed on the FDA’s drug shortage list due to supply constraints at Eli Lilly. The shortage timeline and resolution have followed their own schedule, separate from semaglutide. As of early 2026, the status of tirzepatide on the shortage list has also been in flux, with Eli Lilly pushing for removal and compounders arguing the shortage persists.

The legal dynamics are similar but not identical. Eli Lilly has pursued its own legal actions against compounders, though the specifics of each case differ based on patent portfolios, formulation claims, and the particular pharmacies involved.

If you are currently on compounded tirzepatide, the same principles apply: check whether tirzepatide is currently on the FDA shortage list, verify your pharmacy’s 503A or 503B status, and stay aware of legal developments. Our comparison of compounded vs. brand-name GLP-1s covers the broader differences between these options.

What Happens to Patients on Compounded Semaglutide Now

If you are currently getting compounded semaglutide from a telehealth provider, here is what you need to know:

Your provider may switch you to a different formulation. Many telehealth companies that built their businesses on compounded semaglutide have been pivoting. Some now offer brand-name Wegovy or Ozempic (at higher prices, typically with insurance billing). Others have shifted to compounded tirzepatide where still available. A few have started offering different compounded formulations that combine semaglutide with other ingredients to argue they are not “essentially a copy” of the brand product.

Your pharmacy may stop filling. Some compounding pharmacies have already stopped producing semaglutide in response to legal pressure. If yours stops, you will need to find an alternative source or switch to the brand-name version.

You will not face legal consequences as a patient. The legal actions target pharmacies and providers, not individual patients. Obtaining a compounded medication through a licensed pharmacy with a valid prescription is not illegal for the patient, regardless of the drug’s shortage list status.

The price will likely go up. As compounding options narrow, the remaining providers are raising prices. The days of $149 per month compounded semaglutide may be ending. Many patients are finding the gap between compounded and brand-name pricing is shrinking, though brand-name without insurance remains far more expensive. For strategies on managing these costs, see our GLP-1 cost guide and our guide to using FSA and HSA for GLP-1s.

The Price Gap: Compounded vs. Brand-Name in 2026

The cost difference is the main reason patients seek compounded semaglutide in the first place.

The math is straightforward. For patients without insurance coverage, brand-name semaglutide costs 4 to 9 times more than compounded versions. That price gap is why compounded semaglutide became a billion-dollar market and why patients are anxious about losing access.

The good news: insurance coverage for GLP-1 medications has improved significantly since 2022. More employer plans and even some state Medicaid programs now cover Wegovy for weight management. Our insurance coverage guide and GLP-1 without insurance guide break down your options in detail.

How to Verify Your Compounding Pharmacy Is Legitimate

Whether compounded semaglutide remains available to you or not, verifying your pharmacy is legitimate is critical. Not all compounders are equal, and quality control varies.

Check state board licensing. Every compounding pharmacy must be licensed by the state pharmacy board where it operates. You can verify this on your state’s board of pharmacy website. If a pharmacy cannot produce a license number, walk away.

Look for PCAB accreditation. The Pharmacy Compounding Accreditation Board (PCAB) provides voluntary accreditation that indicates a pharmacy meets quality standards beyond the minimum state requirements. Not all legitimate pharmacies have PCAB accreditation, but it is a strong positive signal.

Verify 503B registration with the FDA. If your pharmacy claims to be a 503B outsourcing facility, you can verify this on the FDA’s website. The FDA maintains a public list of registered outsourcing facilities. If a pharmacy claims 503B status but is not on that list, that is a red flag.

Ask about testing. Reputable compounding pharmacies test their products for potency, sterility (for injectables), and purity. Ask your pharmacy what third-party testing they perform and whether they can provide certificates of analysis. Any pharmacy that refuses to discuss testing should be avoided.

Watch for these warning signs:

• Prices significantly below the $149 to $299 range that most legitimate compounders charge
• No requirement for a prescription or medical consultation
• Claims that their product is “FDA-approved” (compounded drugs are not FDA-approved by definition)
• Inability to provide pharmacy license or accreditation details
• Shipping from outside the United States

What You Should Do Now

If you are on compounded semaglutide or considering it, here are the practical steps:

1. Check the current FDA shortage list. Visit the FDA’s drug shortage database (accessible on fda.gov) and search for semaglutide. This will tell you the current status and which specific dosage forms are still listed.

2. Ask your provider about their pharmacy’s status. Find out whether your telehealth provider uses a 503A or 503B pharmacy and what their plan is if compounded semaglutide becomes unavailable through their current source.

3. Explore insurance coverage. If you have not checked your insurance for brand-name GLP-1 coverage recently, do it now. Coverage has expanded. Our provider directory shows which platforms help with insurance billing and prior authorizations.

4. Have a backup plan. Do not wait until your supply runs out to figure out alternatives. Whether that means switching to a brand-name version, exploring tirzepatide options, or finding a different provider, start researching now.

5. Keep your prescription active. If you are currently on semaglutide (compounded or brand), maintaining an active patient relationship with a licensed provider ensures continuity of care regardless of how the compounding market shifts.

FAQ

Is it legal to buy compounded semaglutide in 2026?

The legality depends on the FDA’s current drug shortage list status and the type of pharmacy producing it. When semaglutide is on the shortage list, both 503A and 503B compounding pharmacies can legally produce it. When it is removed from the shortage list, the legal basis narrows significantly. As a patient, obtaining a compounded medication with a valid prescription from a licensed pharmacy does not expose you to legal risk. The regulatory and legal actions target pharmacies and providers, not patients.

What is the difference between 503A and 503B compounding pharmacies?

503A pharmacies compound medications based on individual patient prescriptions and are primarily regulated at the state level. 503B pharmacies (outsourcing facilities) are FDA-registered and can produce medications in bulk without patient-specific prescriptions. 503B facilities follow FDA manufacturing standards (cGMP). Both types can compound drugs on the FDA shortage list, but 503B facilities face different regulatory requirements and may have more legal flexibility in how they formulate products.

Can Novo Nordisk sue me for using compounded semaglutide?

No. Novo Nordisk’s legal actions target compounding pharmacies, telehealth providers, and distributors, not individual patients. If you have a valid prescription and obtain your medication from a licensed pharmacy, you are not at legal risk. The lawsuits focus on trademark infringement, patent violations, and FDCA compounding regulations as they apply to the entities producing and selling the products.

Will compounded semaglutide be completely unavailable in 2026?

Not necessarily. Even if semaglutide is fully removed from the FDA shortage list, some compounders may continue operating under legal arguments about formulation differences (such as combining semaglutide with other active ingredients). The legal situation is still being settled through ongoing litigation. Availability will likely decrease compared to the peak in 2023 and 2024, and prices may increase, but a complete shutdown of all compounded semaglutide is unlikely in the near term.

How do I switch from compounded to brand-name semaglutide?

Work with your prescribing provider to transition. The active ingredient is the same, but dosing may differ between compounded formulations and brand-name products like Wegovy or Ozempic. Your provider can write a new prescription for the brand-name version and help with insurance prior authorization if needed. Expect a price increase unless your insurance covers the brand-name drug. Many providers in our directory can help with this transition and insurance navigation.

Related

Guides:

• Cheapest GLP-1 Online · Insurance Coverage · GLP-1 Without Insurance
• Compounded vs. Brand-Name GLP-1 · GLP-1 Cost Guide · FSA/HSA for GLP-1s
• Medicare Coverage · Side Effects · Mounjaro Dosage Guide

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides